Patent woes problem for BMS CEO Dolan?
Less than one month ago, the Newark Star-Ledger praised BMS CEO Dolan.
On September 5, 2006, the AP began a story: Some on Wall Street are betting Bristol-Myers Squibb Co. Chief Executive Peter Dolan will soon be out of a job.
Part of the problem is that the reality of what happened with PLAVIX is sinking in.
The AP report also stated:
While the company won a court ruling last week cutting off sales of a generic version of Plavix, the company's best selling drug, earlier missteps in the negotiations triggered a sharp decline in its earnings forecast. Coming on top of an accounting scandal that cost the company $800 million, and the perception that he overpaid for two pharmaceutical investments, Dolan's survival could hang in the balance at a board meeting next week.
If the PLAVIX case goes to a final decision, there may be some insight on the future of the "chiral switch."
On September 5, 2006, the AP began a story: Some on Wall Street are betting Bristol-Myers Squibb Co. Chief Executive Peter Dolan will soon be out of a job.
Part of the problem is that the reality of what happened with PLAVIX is sinking in.
The AP report also stated:
While the company won a court ruling last week cutting off sales of a generic version of Plavix, the company's best selling drug, earlier missteps in the negotiations triggered a sharp decline in its earnings forecast. Coming on top of an accounting scandal that cost the company $800 million, and the perception that he overpaid for two pharmaceutical investments, Dolan's survival could hang in the balance at a board meeting next week.
If the PLAVIX case goes to a final decision, there may be some insight on the future of the "chiral switch."
posted by Lawrence B. Ebert at 5:29 PM
0 Comments:
Post a Comment
<< Home